## Dagmar Stoiber

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6618035/publications.pdf

Version: 2024-02-01

		185998	197535
51	3,152	28	49
papers	citations	h-index	g-index
51	51	51	5714
all docs	docs citations	times ranked	citing authors

#	Article	lF	CITATIONS
1	Integration of interferon- $\hat{l}\pm\hat{l}^2$ signalling to p53 responses in tumour suppression and antiviral defence. Nature, 2003, 424, 516-523.	13.7	814
2	A novel Ncr1-Cre mouse reveals the essential role of STAT5 for NK-cell survival and development. Blood, 2011, 117, 1565-1573.	0.6	193
3	Production of Type I IFN Sensitizes Macrophages to Cell Death Induced by (i>Listeria monocytogenes (i). Journal of Immunology, 2002, 169, 6522-6529.	0.4	144
4	STAT1 acts as a tumor promoter for leukemia development. Cancer Cell, 2006, 10, 77-87.	7.7	136
5	Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesis. Nature Communications, 2015, 6, 6285.	5.8	124
6	Type I Interferons and Natural Killer Cell Regulation in Cancer. Frontiers in Immunology, 2017, 8, 304.	2.2	113
7	Afatinib restrains K-RAS–driven lung tumorigenesis. Science Translational Medicine, 2018, 10, .	5.8	99
8	Non-parenchymal TREM-2 protects the liver from immune-mediated hepatocellular damage. Gut, 2019, 68, 533-546.	6.1	96
9	<i>Listeria monocytogenes</i> Modulates Macrophage Cytokine Responses Through STAT Serine Phosphorylation and the Induction of Suppressor of Cytokine Signaling 3. Journal of Immunology, 2001, 166, 466-472.	0.4	91
10	Type I Interferon Signaling Prevents IL- $1\hat{l}^2$ -Driven Lethal Systemic Hyperinflammation during Invasive Bacterial Infection of Soft Tissue. Cell Host and Microbe, 2016, 19, 375-387.	5.1	88
11	Tyrosine kinase 2 (TYK2) in cytokine signalling and host immunity. Frontiers in Bioscience - Landmark, 2011, 16, 3224.	3.0	85
12	The AP-1-BATF and -BATF3 module is essential for growth, survival and TH17/ILC3 skewing of anaplastic large cell lymphoma. Leukemia, 2018, 32, 1994-2007.	3.3	70
13	Platelet-Leukocyte Interplay in Cancer Development and Progression. Cells, 2020, 9, 855.	1.8	63
14	JAK–STAT inhibition impairs Kâ€RASâ€driven lung adenocarcinoma progression. International Journal of Cancer, 2019, 145, 3376-3388.	2.3	54
15	Natural killer cell-intrinsic type I IFN signaling controls Klebsiella pneumoniae growth during lung infection. PLoS Pathogens, 2017, 13, e1006696.	2.1	54
16	Conditional IFNAR1 ablation reveals distinct requirements of Type I IFN signaling for NK cell maturation and tumor surveillance. Oncolmmunology, 2012, 1, 1027-1037.	2.1	53
17	Antagonistic effects of selenium and lipid peroxides on growth control in early hepatocellular carcinoma. Hepatology, 2012, 55, 1112-1121.	3.6	52
18	TYK2 is a key regulator of the surveillance of B lymphoid tumors. Journal of Clinical Investigation, 2004, 114, 1650-1658.	3.9	50

#	Article	IF	Citations
19	Conditional Stat1 Ablation Reveals the Importance of Interferon Signaling for Immunity to Listeria monocytogenes Infection. PLoS Pathogens, 2012, 8, e1002763.	2.1	49
20	STAT3 isoforms: Alternative fates in cancer?. Cytokine, 2019, 118, 27-34.	1.4	49
21	Leukemic challenge unmasks a requirement for PI3Kδin NK cell–mediated tumor surveillance. Blood, 2008, 112, 4655-4664.	0.6	48
22	Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma. Leukemia, 2019, 33, 696-709.	3.3	40
23	Putting the brakes on mammary tumorigenesis: Loss of STAT1 predisposes to intraepithelial neoplasias. Oncotarget, 2011, 2, 1043-1054.	0.8	40
24	ETV6/RUNX1 Induces Reactive Oxygen Species and Drives the Accumulation of DNA Damage in B Cells. Neoplasia, 2013, 15, 1292-IN28.	2.3	39
25	Type I interferons have opposing effects during the emergence and recovery phases of colitis. European Journal of Immunology, 2014, 44, 2749-2760.	1.6	39
26	Jak1 deficiency leads to enhanced Abelson-induced B-cell tumor formation. Blood, 2003, 101, 4937-4943.	0.6	33
27	TYK2 is a key regulator of the surveillance of B lymphoid tumors. Journal of Clinical Investigation, 2004, 114, 1650-1658.	3.9	32
28	Dendritic Cells Require STAT-1 Phosphorylated at Its Transactivating Domain for the Induction of Peptide-Specific CTL. Journal of Immunology, 2009, 183, 2286-2293.	0.4	31
29	The cooperating mutation or "second hit―determines the immunologic visibility toward MYC-induced murine lymphomas. Blood, 2011, 118, 4635-4645.	0.6	30
30	The Transcription Factor ZNF683/HOBIT Regulates Human NK-Cell Development. Frontiers in Immunology, 2017, 8, 535.	2.2	30
31	Identification of an Indispensable Role for Tyrosine Kinase 2 in CTL-Mediated Tumor Surveillance. Cancer Research, 2009, 69, 203-211.	0.4	29
32	Beneficial Metabolic Effects of TREM2 in Obesity Are Uncoupled From Its Expression on Macrophages. Diabetes, 2021, 70, 2042-2057.	0.3	26
33	Impact of glutathione peroxidase 4 on cell proliferation, angiogenesis and cytokine production in hepatocellular carcinoma. Oncotarget, 2018, 9, 10054-10068.	0.8	25
34	Impact of Single or Combined Genomic Alterations of TP53, MYC, and BCL2 on Survival of Patients With Diffuse Large B-Cell Lymphomas. Medicine (United States), 2015, 94, e2388.	0.4	24
35	CGRP Signaling via CALCRL Increases Chemotherapy Resistance and Stem Cell Properties in Acute Myeloid Leukemia. International Journal of Molecular Sciences, 2019, 20, 5826.	1.8	22
36	Super-enhancer-based identification of a BATF3/IL-2Râ° module reveals vulnerabilities in anaplastic large cell lymphoma. Nature Communications, 2021, 12, 5577.	5.8	21

#	Article	IF	Citations
37	STAT3 $\hat{I}^2$ is a tumor suppressor in acute myeloid leukemia. Blood Advances, 2019, 3, 1989-2002.	2.5	20
38	Genetic alterations in glucocorticoid signaling pathway components are associated with adverse prognosis in children with relapsed <i>ETV6/RUNX1</i> -positive acute lymphoblastic leukemia. Leukemia and Lymphoma, 2016, 57, 1163-1173.	0.6	18
39	The MAPK-Activated Kinase MK2 Attenuates Dendritic Cell–Mediated Th1 Differentiation and Autoimmune Encephalomyelitis. Journal of Immunology, 2015, 195, 541-552.	0.4	17
40	A mouse model to identify cooperating signaling pathways in cancer. Nature Methods, 2012, 9, 897-900.	9.0	15
41	Untwining Anti-Tumor and Immunosuppressive Effects of JAK Inhibitorsâ€"A Strategy for Hematological Malignancies?. Cancers, 2021, 13, 2611.	1.7	15
42	<scp>AKT</scp> 3 drives adenoid cystic carcinoma development in salivary glands. Cancer Medicine, 2018, 7, 445-453.	1.3	13
43	Myeloid Cells Restrict MCMV and Drive Stress-Induced Extramedullary Hematopoiesis through STAT1. Cell Reports, 2019, 26, 2394-2406.e5.	2.9	12
44	The Multifaceted Role of STAT3 in NK-Cell Tumor Surveillance. Frontiers in Immunology, 0, 13, .	2.2	11
45	Commentary on H. Ide et al., "Tyk2 expression and its signaling enhances the invasiveness of prostate cancer cellsâ€. Biochemical and Biophysical Research Communications, 2008, 366, 869-870.	1.0	10
46	Down-regulation of A20 promotes immune escape of lung adenocarcinomas. Science Translational Medicine, 2021, 13, .	5.8	10
47	The Ups and Downs of STAT Inhibition in Acute Myeloid Leukemia. Biomedicines, 2021, 9, 1051.	1.4	10
48	Tumor suppressors in acute myeloid leukemia. Leukemia and Lymphoma, 2021, 62, 2320-2330.	0.6	6
49	Cooperation of ETV6/RUNX1 and BCL2 enhances immunoglobulin production and accelerates glomerulonephritis in transgenic mice. Oncotarget, 2016, 7, 12191-12205.	0.8	6
50	A Mouse Model to Assess STAT3 and STAT5A/B Combined Inhibition in Health and Disease Conditions. Cancers, 2019, 11, 1226.	1.7	3
51	Methods to Study Tumor Surveillance Using Tumor Cell Transplantation into Genetically Engineered Mice. Methods in Molecular Biology, 2015, 1267, 439-456.	0.4	0